Kerui Wu, Ph.D.
- Assistant Professor, Nanoscience
- (336) 285-2865
About Professor Wu
Dr. Wu became a member of JSNN in August 2023, following the culmination of his postdoctoral research at Wake Forest University’s Department of Cancer Biology, where he served as an NIH T32 Postdoctoral Research Fellow. Holding an undergraduate degree in Clinical Medicine from Nanjing Medical University and a doctorate in Cancer Biology from Wake Forest University, Dr. Wu has devoted his academic journey to investigating the intricate molecular underpinnings of tumor progression and metastasis in solid malignancies. His scholarly pursuit has also been dedicated to pioneering innovative therapeutic approaches aimed at transforming the landscape of disease treatment.
- Pioneering New Frontiers in Cancer Treatment through Synthetic Biology
At the forefront of cancer treatment advancement, Dr. Wu’s research harnesses the power of synthetic biology to propel immunotherapeutic solutions. A cornerstone of this endeavor lies in the meticulous creation of an engineered nanovesicle, poised to herald a new approach of personalized immunotherapy tailored to combat an array of solid tumors. This research unfolds a compelling narrative in the realm of personalized cancer immunotherapy, accentuating the augmentation of antigen presentation mechanisms and the amplification of tumor-specific immune cell populations.
- Exploring Tumor Microenvironment’s Role in Cancer Progression
Dr. Wu’s research is an intricate journey into the core of cancer advancement. Focusing on the interplay between cancer cells and their microenvironment, he uncovers hidden messengers like nanovesicles, shaping the environment for cancer’s growth. These molecules serve as diagnostic whispers and promise novel therapies, illuminating the path toward advanced cancer treatments.
Honors & Awards
- 2023 NIH T32 Postdoctoral Research Fellowship
- 2023 Top-10 Women’s Health Research of WFU
- 2023 Comprehensive Cancer Center Fellows Cancer Center Research Symposium Best Presentation Award
- 2022 Director’s Excellence in Cancer Research Award
Wu, Kerui, et al. “Engineering an active immunotherapy for personalized cancer treatment and prevention of recurrence.” Science Advances 9.17 (2023): eade0625.
Zhao, Dan*, Wu, Kerui*, et al. “Exosomal miR-1304-3p promotes breast cancer progression in African Americans by activating cancer-associated adipocytes.” Nature Communications 13.1 (2022): 7734. (*co-first authors)
Wu, Kerui, et al. “Exosomal miR-19a and IBSP cooperate to induce osteolytic bone metastasis of estrogen receptor-positive breast cancer.” Nature Communications 12.1 (2021): 5196.
Wu, Kerui, et al. “Extracellular vesicles as emerging targets in cancer: Recent development from bench to bedside.” Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 1868.2 (2017): 538-563.
Wu, Kerui, et al. “Non-coding RNAs in cancer brain metastasis.” Frontiers in bioscience (Scholar edition) 8 (2016): 187.
Wu, Kerui, et al. “Roles of the cyclooxygenase 2 matrix metalloproteinase 1 pathway in brain metastasis of breast cancer.” Journal of Biological Chemistry 290.15 (2015): 9842-9854.